









Mercado
/
Acciones
/
nasdaq-mnpr
/

Monopar Therapeutics Inc

MNPR

80.950USD

+0.190+0.24%

Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min

496.02MCap. mercado

PérdidaP/E TTM



Monopar Therapeutics Inc

80.950

+0.190+0.24%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Monopar Therapeutics Inc Compañía

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Información de Monopar Therapeutics Inc



Símbolo de cotizaciónMNPR

Nombre de la empresaMonopar Therapeutics Inc

Fecha de salida a bolsaDec 19, 2019

Director ejecutivoDr. Chandler D. Robinson, M.D.

Número de empleados16

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 19

Dirección1000 Skokie Blvd Ste 350

CiudadWILMETTE

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal60091-1146

Teléfono18473880349

Sitio Webhttps://www.monopartx.com/

Símbolo de cotizaciónMNPR

Fecha de salida a bolsaDec 19, 2019

Director ejecutivoDr. Chandler D. Robinson, M.D.

Ejecutivos de Monopar Therapeutics Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

79.42K

+8.10%

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

Ms. Lavina Talukdar

Independent Director

14.00K

Ms. Kim R. Tsuchimoto

Director

11.49K

Mr. Arthur J. Klausner

Independent Director

6.17K

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

Mr. Vu Quan

Chief Financial Officer, Principal Accounting Officer

Dr. Patrice P. Rioux, M.D., Ph.D.

Acting Chief Medical Officer

Mr. Andrew J. Cittadine

Chief Operating Officer

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

79.42K

+8.10%

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

Ms. Lavina Talukdar

Independent Director

14.00K

Ms. Kim R. Tsuchimoto

Director

11.49K

Mr. Arthur J. Klausner

Independent Director

6.17K

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

Desglose de ingresos

Sin datos

Sin datos

Por negocio

Por región

Sin datos

Estadísticas de accionistas

Actualizado: mar., 19 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

Janus Henderson Investors

17.73%

Gem Pharmaceuticals LLC

9.24%

Adage Capital Management, L.P.

9.06%

RA Capital Management, LP

7.73%

AstraZeneca PLC

5.86%

Otro

50.37%

Accionistas

Proporción

Janus Henderson Investors

17.73%

Gem Pharmaceuticals LLC

9.24%

Adage Capital Management, L.P.

9.06%

RA Capital Management, LP

7.73%

AstraZeneca PLC

5.86%

Otro

50.37%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor/Hedge Fund

20.88%

Corporation

19.21%

Hedge Fund

14.05%

Venture Capital

7.73%

Investment Advisor

5.43%

Individual Investor

4.80%

Research Firm

0.19%

Pension Fund

0.12%

Bank and Trust

0.06%

Otro

27.52%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

3.34M

50.46%

+135.23K

2025Q2

5.07M

82.91%

-355.61K

2025Q1

5.03M

83.96%

+455.96K

2024Q4

4.84M

79.28%

+1.76M

2024Q3

1.90M

50.69%

+25.14K

2024Q2

1.96M

52.51%

+123.52K

2024Q1

1.91M

52.92%

+136.66K

2023Q4

1.88M

67.20%

+125.61K

2023Q3

1.87M

67.45%

+153.91K

2023Q2

1.84M

66.75%

+138.58K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Janus Henderson Investors

1.17M

17.73%

+37.96K

+3.35%

Jun 30, 2025

Gem Pharmaceuticals LLC

611.08K

9.24%

Apr 04, 2025

Adage Capital Management, L.P.

599.20K

9.06%

Jun 30, 2025

RA Capital Management, LP

511.21K

7.73%

Jun 30, 2025

AstraZeneca PLC

387.33K

5.86%

+387.33K

Oct 23, 2024

Tactic Pharma LLC

272.03K

4.11%

-550.23K

-66.92%

Sep 24, 2025

The Vanguard Group, Inc.

86.49K

1.31%

+31.25K

+56.59%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

183.97K

2.78%

+175.22K

+2003.49%

Jun 30, 2025

Point72 Asset Management, L.P.

104.02K

1.57%

-64.14K

-38.14%

Jun 30, 2025

Adar1 Capital Management LLC

100.97K

1.53%

+200.00

+0.20%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

iShares Micro-Cap ETF

0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.05%

iShares Russell 2000 Growth ETF

0.02%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 ETF

0.01%

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

Proporción0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proporción0.05%

iShares Russell 2000 Growth ETF

Proporción0.02%

Proshares Ultra Russell 2000

Proporción0.01%

Global X Russell 2000 ETF

Proporción0.01%

ProShares Hedge Replication ETF

Proporción0.01%

ProShares UltraPro Russell2000

Proporción0.01%

iShares Russell 2000 ETF

Proporción0.01%

Avantis US Small Cap Equity ETF

Proporción0%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Fecha

Tipo

Relación

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

Aug 09, 2024

Merger

5→1

KeyAI

